137. Clin Cancer Res. 2018 Aug 1;24(15):3483-3485. doi: 10.1158/1078-0432.CCR-18-1114.Epub 2018 May 25.Neratinib: Inching Up on the Cure Rate of HER2+ Breast Cancer?Unni N(1), Sudhan DR(2), Arteaga CL(3)(4).Author information: (1)Department of Medicine, UT Southwestern Medical Center, Dallas, Texas.(2)Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt UniversityMedical Center, Nashville, Tennessee.(3)Department of Medicine, UT Southwestern Medical Center, Dallas, Texas.carlos.arteaga@utsouthwestern.edu.(4)Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center,Dallas, Texas.Neratinib was recently approved by the FDA for extended adjuvant treatment ofHER2+ breast cancer. The ExteNET trial showed improvement in invasivedisease-free survival (iDFS) in the neratinib arm compared with placebo. Thebenefit was more pronounced in patients with estrogen receptor-positive(ER+)/HER2+ tumors, suggesting bidirectional cross-talk between the ER and HERpathways. Clin Cancer Res; 24(15); 3483-5. ©2018 AACRSee related article by Singhet al., p. 3486.©2018 American Association for Cancer Research.DOI: 10.1158/1078-0432.CCR-18-1114 PMID: 29802101 